Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result

The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thir...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of community genetics 2019-10, Vol.10 (4), p.501-514
Hauptverfasser: Stafford, Lesley, Flehr, Alison, Judd, Fiona, Lindeman, Geoffrey J., Gibson, Penny, Komiti, Angela, Mann, G. Bruce, Kentwell, Maira
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 514
container_issue 4
container_start_page 501
container_title Journal of community genetics
container_volume 10
creator Stafford, Lesley
Flehr, Alison
Judd, Fiona
Lindeman, Geoffrey J.
Gibson, Penny
Komiti, Angela
Mann, G. Bruce
Kentwell, Maira
description The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.
doi_str_mv 10.1007/s12687-019-00415-w
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6754479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2294511341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEolXpH-CALHHhEuqJPxJfkMqqQKVKSAgkbpbjjLepEnuxnd32yi_HsNvyccAHe-R55vWM36p6DvQ1UNqeJWhk19YUVE0pB1HvHlXH0MmulpTC40PMgH49qk5TuqFlMQZCiqfVEaMKFGv4cfX94naDcURvMRHjBzL6jHETMZs8Bp9IcOTtp9U5nDUkY8qjXxMzh7LvwoyeGOfQZhxIf0f6iCZlEiIJWxNH44k1RTeS3XUgES2O2wIa4nFdxLdY7tIy5WfVE2emhKeH86T68u7i8-pDffXx_eXq_Kq2vOW5Vj2WCcDJfpCm6VregOiF5cL1gMCHlivppBxQiKYzyDgqyoyyFlvn2p6xk-rNXnez9DMOFn2OZtKbOM4m3ulgRv13xo_Xeh22WraC81YVgVcHgRi-LeUz9Dwmi9NkPIYl6QaUgtKYFAV9-Q96E5boy3i6aRQXAIxDoZo9ZWNIKaJ7aAao_umy3rusi8v6l8t6V4pe_DnGQ8m9pwVgeyCVlF9j_P32f2R_AJUrtT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2294511341</pqid></control><display><type>article</type><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</creator><creatorcontrib>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</creatorcontrib><description>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</description><identifier>ISSN: 1868-310X</identifier><identifier>EISSN: 1868-6001</identifier><identifier>DOI: 10.1007/s12687-019-00415-w</identifier><identifier>PMID: 30919324</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Anxiety ; Biomedical and Life Sciences ; Biomedicine ; BRCA1 protein ; Breast cancer ; Epidemiology ; Gene Function ; Gene Therapy ; Genetic counseling ; Genetic screening ; Human Genetics ; Morbidity ; Original ; Original Article ; Ovarian cancer ; Public Health ; Quality of life ; Womens health</subject><ispartof>Journal of community genetics, 2019-10, Vol.10 (4), p.501-514</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2019</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</citedby><cites>FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</cites><orcidid>0000-0002-6460-9881</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754479/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754479/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51298,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30919324$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stafford, Lesley</creatorcontrib><creatorcontrib>Flehr, Alison</creatorcontrib><creatorcontrib>Judd, Fiona</creatorcontrib><creatorcontrib>Lindeman, Geoffrey J.</creatorcontrib><creatorcontrib>Gibson, Penny</creatorcontrib><creatorcontrib>Komiti, Angela</creatorcontrib><creatorcontrib>Mann, G. Bruce</creatorcontrib><creatorcontrib>Kentwell, Maira</creatorcontrib><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><title>Journal of community genetics</title><addtitle>J Community Genet</addtitle><addtitle>J Community Genet</addtitle><description>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</description><subject>Anxiety</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>BRCA1 protein</subject><subject>Breast cancer</subject><subject>Epidemiology</subject><subject>Gene Function</subject><subject>Gene Therapy</subject><subject>Genetic counseling</subject><subject>Genetic screening</subject><subject>Human Genetics</subject><subject>Morbidity</subject><subject>Original</subject><subject>Original Article</subject><subject>Ovarian cancer</subject><subject>Public Health</subject><subject>Quality of life</subject><subject>Womens health</subject><issn>1868-310X</issn><issn>1868-6001</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEolXpH-CALHHhEuqJPxJfkMqqQKVKSAgkbpbjjLepEnuxnd32yi_HsNvyccAHe-R55vWM36p6DvQ1UNqeJWhk19YUVE0pB1HvHlXH0MmulpTC40PMgH49qk5TuqFlMQZCiqfVEaMKFGv4cfX94naDcURvMRHjBzL6jHETMZs8Bp9IcOTtp9U5nDUkY8qjXxMzh7LvwoyeGOfQZhxIf0f6iCZlEiIJWxNH44k1RTeS3XUgES2O2wIa4nFdxLdY7tIy5WfVE2emhKeH86T68u7i8-pDffXx_eXq_Kq2vOW5Vj2WCcDJfpCm6VregOiF5cL1gMCHlivppBxQiKYzyDgqyoyyFlvn2p6xk-rNXnez9DMOFn2OZtKbOM4m3ulgRv13xo_Xeh22WraC81YVgVcHgRi-LeUz9Dwmi9NkPIYl6QaUgtKYFAV9-Q96E5boy3i6aRQXAIxDoZo9ZWNIKaJ7aAao_umy3rusi8v6l8t6V4pe_DnGQ8m9pwVgeyCVlF9j_P32f2R_AJUrtT8</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Stafford, Lesley</creator><creator>Flehr, Alison</creator><creator>Judd, Fiona</creator><creator>Lindeman, Geoffrey J.</creator><creator>Gibson, Penny</creator><creator>Komiti, Angela</creator><creator>Mann, G. Bruce</creator><creator>Kentwell, Maira</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6460-9881</orcidid></search><sort><creationdate>20191001</creationdate><title>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</title><author>Stafford, Lesley ; Flehr, Alison ; Judd, Fiona ; Lindeman, Geoffrey J. ; Gibson, Penny ; Komiti, Angela ; Mann, G. Bruce ; Kentwell, Maira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-9be0031f6bd6a2874215b5c45fb1e14d7496f66de5528ae34e903a9cce7ff7b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anxiety</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>BRCA1 protein</topic><topic>Breast cancer</topic><topic>Epidemiology</topic><topic>Gene Function</topic><topic>Gene Therapy</topic><topic>Genetic counseling</topic><topic>Genetic screening</topic><topic>Human Genetics</topic><topic>Morbidity</topic><topic>Original</topic><topic>Original Article</topic><topic>Ovarian cancer</topic><topic>Public Health</topic><topic>Quality of life</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stafford, Lesley</creatorcontrib><creatorcontrib>Flehr, Alison</creatorcontrib><creatorcontrib>Judd, Fiona</creatorcontrib><creatorcontrib>Lindeman, Geoffrey J.</creatorcontrib><creatorcontrib>Gibson, Penny</creatorcontrib><creatorcontrib>Komiti, Angela</creatorcontrib><creatorcontrib>Mann, G. Bruce</creatorcontrib><creatorcontrib>Kentwell, Maira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of community genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stafford, Lesley</au><au>Flehr, Alison</au><au>Judd, Fiona</au><au>Lindeman, Geoffrey J.</au><au>Gibson, Penny</au><au>Komiti, Angela</au><au>Mann, G. Bruce</au><au>Kentwell, Maira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result</atitle><jtitle>Journal of community genetics</jtitle><stitle>J Community Genet</stitle><addtitle>J Community Genet</addtitle><date>2019-10-01</date><risdate>2019</risdate><volume>10</volume><issue>4</issue><spage>501</spage><epage>514</epage><pages>501-514</pages><issn>1868-310X</issn><eissn>1868-6001</eissn><abstract>The aim of this study was to retrospectively describe the genetic testing motives and experiences of women with a previous breast and/or ovarian cancer diagnosis, who received negative BRCA1/2 results including variants of unknown significance and no pathogenic variant detected. One hundred and thirteen women (mean age 56.17 years) were recruited from a familial cancer centre in metropolitan Australia, an average 3.4 years after undergoing testing. Participants completed a self-report questionnaire focusing on the retrospective experience of and motives for undergoing BRCA1/2 testing. The study found that the primary motives for undergoing BRCA1/2 testing were (a) to know more about whether their cancer was hereditary, and (b) to have more certainty about the risk of their children developing cancer. In terms of perceptions of personal risk, 35% of women perceived that their risk of breast cancer to be the same or lower than the general population and 80% believed the negative test result to mean that a risk-conferring gene had not been detected. Yet, the average estimate of the likelihood that their cancer was hereditary was 48 out of a possible 100. Psychologically, women did not interpret the negative BRCA1/2 result as a positive outcome. Half were not relieved by the result and were as or more worried than before. Psychological morbidity was high with 17%, 100%, and 36% experiencing clinically significant depression, anxiety, and cancer-specific distress, respectively. Self-ratings of the likelihood that their cancer was hereditary were more closely associated with their personal family cancer histories than with measures of psychological distress. These results have implications for adherence to risk-reducing behaviours and quality of life. Given that these women are not routinely followed up in clinical practice, these findings highlight the importance of post-test genetic counselling and longer-term follow-up for women with negative BRCA1/2 results. Additional time and emotional support from genetic counsellors may help this group of women make sense of the meaning of their test result and adjust psychologically, particularly to uncertainty around the cause of their family history.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30919324</pmid><doi>10.1007/s12687-019-00415-w</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6460-9881</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1868-310X
ispartof Journal of community genetics, 2019-10, Vol.10 (4), p.501-514
issn 1868-310X
1868-6001
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6754479
source Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Anxiety
Biomedical and Life Sciences
Biomedicine
BRCA1 protein
Breast cancer
Epidemiology
Gene Function
Gene Therapy
Genetic counseling
Genetic screening
Human Genetics
Morbidity
Original
Original Article
Ovarian cancer
Public Health
Quality of life
Womens health
title Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T14%3A48%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Experiences%20and%20interpretations%20of%20BRCA1/2%20testing%20among%20women%20affected%20by%20breast%20or%20ovarian%20cancer%20who%20received%20a%20negative%20result&rft.jtitle=Journal%20of%20community%20genetics&rft.au=Stafford,%20Lesley&rft.date=2019-10-01&rft.volume=10&rft.issue=4&rft.spage=501&rft.epage=514&rft.pages=501-514&rft.issn=1868-310X&rft.eissn=1868-6001&rft_id=info:doi/10.1007/s12687-019-00415-w&rft_dat=%3Cproquest_pubme%3E2294511341%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2294511341&rft_id=info:pmid/30919324&rfr_iscdi=true